Discover the most-read SMA stories of 2025, featuring updates on the gene therapy Zolgensma, next-generation treatments, and ...

Findings from two clinical trials suggest Novartis' Itvisma is safe and effective for SMA patients over 2 years old.

Investing.com - HSBC downgraded Biogen (NASDAQ:BIIB) from Hold to Reduce on Wednesday, while slightly lowering its price target to $143.00 from $144.00. This comes despite the stock currently trading ...

CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative ...

Positive CHMP opinion is based on data from the DEVOTE study which evaluated the high dose regimen of nusinersen in treatment-naive participants and those transitioning from the currently approved ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Biogen Inc. is conducting a study titled ...

Treatment with onasemnogene abeparvovec gene therapy for spinal muscular atrophy (SMA) type 1 was associated with less need for nutritional support or nighttime ventilation compared to recommended ...

With significant upside potential, Biogen Inc. (NASDAQ:BIIB) secures a spot on our list of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. Jefferies began covering Biogen Inc.

The authors of a controversial 2022 paper that claimed to measure neuronal activity using functional MRI retracted their work after their reanalysis "did not robustly support the original conclusions.

Biogen Inc. (NASDAQ:BIIB) ranks among the most undervalued NASDAQ stocks to buy now. On September 18, Biogen Inc. (NASDAQ:BIIB) announced that it had finalized a deal to acquire Alcyone Therapeutics ...